Addex GABAB PAM Candidate Shows Solid Anti-Tussive Activity in IPF Chronic Cough Model
ADXN sits 25% above its 52-week low of $5.41 on elevated volume (2.6× avg).
Summary
Addex Therapeutics announced positive preclinical data for its GABAB PAM candidate, demonstrating solid anti-tussive activity in a bleomycin-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. The studies showed robust and sustained efficacy, significant reductions in cough frequency, increased cough latency, and improved lung pathology outcomes, all with a favorable safety profile. This follows the company's announcement last week of robust anti-tussive activity for the same GABAB PAM drug candidate in non-human primate studies, further strengthening the preclinical evidence for the program. For a small clinical-stage biopharmaceutical company like Addex, these positive preclinical results in a relevant disease model are material, de-risking the GABAB PAM program for chronic cough and supporting its therapeutic promise. Investors will now look for updates on the program's advancement into clinical trials and further details on its development pathway.
At the time of this announcement, ADXN was trading at $6.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $5.41 to $12.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.